Ravelcare launches Ravel PRO, AI skincare range; FY26 revenue up 7.9%

scanx
Reviewed by
Naman SScanX News Team
Key Highlights
  • Ravelcare launched Ravel PRO haircare range, contributing ~20% incremental revenue in July
  • FY26 revenue rose 7.9% to ₹2,695.43 lakhs; PAT reached ₹515.40 lakhs
  • AI diagnostic skincare range planned for H2FY27 launch
  • Company remains debt-free with net worth of ₹3,740.84 lakhs
  • IPO proceeds for manufacturing integration held in fixed deposits pending finalisation
powered bylight_fuzz_icon
49305476

*this image is generated using AI for illustrative purposes only.

Ravelcare launched Ravel PRO and announced an AI diagnostic skincare range on August 26, 2026. The new haircare line contributed roughly 20% incremental revenue in its first full month of July. This expansion targets both domestic and international consumers across e-commerce and quick-commerce platforms.

Product Launch Details

The company filed an intimation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations with BSE Limited. The filing details the launch of Ravel PRO, a dermatologist-developed range of twelve products addressing hair fall, dandruff, damage repair, hair growth, and premature greying.

Key product highlights include:

  • Zero Hairfall Shampoo and Conditioner using adenosine-peptide technology
  • Zero Dandruff range featuring ketoconazole and salicylic acid
  • Hyaluronic Repair Shampoo and Conditioner for damage repair
  • Anti Grey Serum claiming up to 93% reduction in premature greying

The Anti-Grey Serum alone sold approximately 3,500 units in its first thirty days. Two additional PRO products are scheduled for launch in September. The AI-led diagnostic skincare range is planned for the second half of FY27.

Financial Performance

For FY26, the company reported revenue of ₹2,695.43 lakhs, representing a 7.9% increase. Profit after tax stood at ₹515.40 lakhs. The balance sheet shows no debt and a net worth of ₹3,740.84 lakhs.

Metric FY26 Value
Revenue ₹2,695.43 lakhs
Revenue Growth 7.9%
Profit After Tax ₹515.40 lakhs
Net Worth ₹3,740.84 lakhs
Debt Status No debt

The second half of FY26 was softer than the first half. Management reduced marketing spend by 19% compared to the previous year's second half to focus on IPO completion, R&D, and new category development. These activities did not contribute to revenue in H2FY26 but laid the groundwork for the current expansion.

Capital Allocation and Future Plans

The December 2025 IPO raised ₹2,410.20 lakhs (₹2,191.10 lakhs net of issue expenses). Funds allocated for backward integration into manufacturing remain unutilised and are held in bank fixed deposits earning interest. Management plans to finalise the plant's scale and configuration after stabilising the new product launches.

The company secured more favourable pricing from its existing manufacturing partner, ensuring no cost impact during recent global supply-chain disruptions. Advance planning of inputs and inventory protected product costs and supply continuity.

Historical Stock Returns for Ravelcare

1 Day5 Days1 Month6 Months1 Year5 Years
+5.77%-1.08%-8.56%-33.77%0.0%0.0%

How will the upcoming AI diagnostic skincare range in H2 FY27 differentiate Ravelcare from established dermatological competitors in the Indian market?

What is the timeline for utilizing the unspent IPO proceeds for backward integration, and how will owning manufacturing capacity impact long-term gross margins?

Given the 19% reduction in marketing spend during H2 FY26, what specific customer acquisition strategies will drive the projected revenue growth from the new PRO line?

Ravelcare reappoints Ayush Varma, Maheshkumar Varma as directors

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Ayush Varma reappointed as Managing Director for a three-year term starting June 20, 2027
  • Maheshkumar Varma reappointed as Whole-time Director for a three-year term starting June 20, 2027
  • Registered office shifted to new location in Malad West, Mumbai, effective August 26, 2026
  • VTSN & Associates LLP appointed as Secretarial Auditor for FY27
powered bylight_fuzz_icon
49209220

*this image is generated using AI for illustrative purposes only.

Ravelcare Ltd board of directors approved the reappointment of key promoters and shifted its registered office during a meeting held on August 25, 2026. The decisions require shareholder approval at the upcoming annual general meeting.

The board, acting on recommendations from the Nomination and Remuneration Committee, renewed the mandates for Mr. Ayush Varma and Mr. Maheshkumar Varma. Both appointments are effective from June 20, 2027, through June 19, 2030.

Director Reappointments

Mr. Ayush Varma, aged 30, was reappointed as Managing Director. He holds a Bachelor of Technology degree in Computer Engineering from K.J. Somaiya College of Engineering. As a promoter and one of the first directors, he brings over six years of experience in the beauty and personal care industry. His responsibilities include business development, strategy formulation, and overseeing core business functions.

Mr. Maheshkumar Varma, aged 57, was reappointed as Whole-time Director. He completed his Higher Secondary Certificate Examination from Brijlal Biyani Science College, Amravati. He operates a proprietary firm named Madhuri Jewellers. At Ravelcare, he oversees strategic decisions, accounting, finance functions, and standard operating procedures.

The filing confirms that both directors are not debarred from holding office by any SEBI order or other authority, in compliance with SEBI guidelines dated June 14, 2018, and Exchange Circular dated June 20, 2018.

Director Role Term Start Term End Relation
Ayush Varma Managing Director June 20, 2027 June 19, 2030 Son of Maheshkumar Varma
Maheshkumar Varma Whole-time Director June 20, 2027 June 19, 2030 Father of Ayush Varma

Corporate Governance Updates

The Audit Committee recommended the appointment of M/s. VTSN & Associates LLP as Secretarial Auditors for the financial year 2026-27. The firm, registered with the Institute of Company Secretaries of India (ICSI), specializes in corporate laws, securities laws, and governance compliance.

Additionally, the board approved shifting the registered office within Mumbai’s jurisdiction. The new address is 12th Floor, Flat 1211, 9 Business Bay, Khakhar Property, Off New Link Road Mindspace, Behind Evershine Mall, Chincholi Bunder, Malad (W), Mumbai-400064. This change takes effect on August 26, 2026.

The board also issued the notice for the 8th Annual General Meeting along with the Directors Report for the year ended March 31, 2026. Mr. Vishal Thawani, Designated Partner of VTSN & Associates LLP, was appointed as Scrutinizer for the e-voting process.

Historical Stock Returns for Ravelcare

1 Day5 Days1 Month6 Months1 Year5 Years
+5.77%-1.08%-8.56%-33.77%0.0%0.0%

How might the three-year tenure extension for the Varma family influence Ravelcare's strategic direction in the competitive beauty and personal care sector?

What operational or logistical advantages does the new registered office location in Malad (W) offer compared to the previous address?

Are there any specific governance reforms or compliance enhancements expected under the newly appointed Secretarial Auditor, VTSN & Associates LLP?

More News on Ravelcare

1 Year Returns:0.00%